Drug PerformanceVoxzogo's continued uptake in achondroplasia and easing supply chain issues contribute to the company's positive prospects.
Financial OutlookAnalyst maintains a Buy rating and $130 price objective for BioMarin, reflecting confidence in the success of Voxzogo and the company's core business.
Operational EfficiencyThere is potential for significant cost savings in operations, which BMRN plans to execute, indicating an opportunity for improved financial efficiency.